$CRDF earnings report

Cardiff Oncology reports Q3 2026 net loss of $(8,857) thousand; Phase 2 onvansertib data continue to mature ahead of planned Phase 3 start. AlphAI read Cardiff Oncology's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readCRDF · Q3 2026 · ended 2026-09-30

Cardiff Oncology reports Q3 2026 net loss of $(8,857) thousand; Phase 2 onvansertib data continue to mature ahead of planned Phase 3 start

→Mixed quarter

Operating expenses fell sharply year to date and the net loss narrowed, but royalty revenue is minimal, cash and short-term investments of approximately $33.8 million fund operations only to the end of Q3 2027, and the Phase 3 start is still a plan rather than a reported event.

Revenue
$171K

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Royalty revenues, three months ended Sep 30, 2026GAAP$171K––
Research and development expenses, three months ended Sep 30, 2026GAAP$5.03M––
Selling, general and administrative expenses, three months ended Sep 30, 2026GAAP$4.36M––
Total operating expenses, three months ended Sep 30, 2026GAAP$9.39M––
Loss from operations, three months ended Sep 30, 2026GAAP−$9.22M––
Interest income, three months ended Sep 30, 2026GAAP$363K––
Net loss, three months ended Sep 30, 2026GAAP−$8.86M––
Net loss attributable to common stockholders, three months ended Sep 30, 2026GAAP−$8.86M––
Net loss per common share, basic and diluted, three months ended Sep 30, 2026GAAP$(0.12) per share––
Royalty revenues, nine months ended Sep 30, 2026GAAP$316K––
Research and development expenses, nine months ended Sep 30, 2026GAAP$17.71M–decrease of $12.5 million
Selling, general and administrative expenses, nine months ended Sep 30, 2026GAAP$14.29M–increase of $3.1 million
Total operating expenses, nine months ended Sep 30, 2026GAAP$32M–decrease of $9.5 million
Loss from operations, nine months ended Sep 30, 2026GAAP−$31.68M––
Interest income, nine months ended Sep 30, 2026GAAP$1.25M––
Net loss, nine months ended Sep 30, 2026GAAP−$30.43M––
Net loss attributable to common stockholders, nine months ended Sep 30, 2026GAAP−$30.45M––
Net loss per common share, basic and diluted, nine months ended Sep 30, 2026GAAP$(0.43) per share––
Cash, cash equivalents and short-term investments, as of Sep 30, 2026otherapproximately $33.8 million––
Net cash used in operating activities, nine months ended Sep 30, 2026otherapproximately $33.9 million–increase of $2.0 million
Total assets, as of Sep 30, 2026 (Dec 31, 2025: $61,884 thousand)GAAP$36.41M––
Stockholders' equity, as of Sep 30, 2026 (Dec 31, 2025: $45,388 thousand)GAAP$28.10M––

Capital returns

  • In July 2026 Cardiff completed a $10 million registered direct offering of common stock and warrants to support working capital and general corporate purposes.
  • The company stated net proceeds of approximately $9.1 million from the July 2026 registered direct offering.
  • No share repurchases or dividends on common stock are reported. The filing shows a preferred stock dividend of $(6) thousand for the three months and $(18) thousand for the nine months, both periods of 2026 and 2025.

What drove it

  • The company attributes the nine-month R&D decrease of $12.5 million to the completion of clinical trials, fewer patients on treatment in the Phase 2 mCRC trial, a reduction in preclinical activities, and completion of CMC activities ahead of the planned Phase 3 mCRC trial.
  • The company states that the nine-month SG&A increase of $3.1 million was driven by legal and professional fees related to its dispute with NMS, which was resolved on September 14, 2026, and by employee severance costs.
  • The company reports that Cardiff and NMS resolved all outstanding disputes regarding global rights to onvansertib and amended their 2017 exclusive license agreement in September 2026.
  • The company reports that the median PFS has not been reached in the 30 mg onvansertib plus FOLFIRI/bev arm, versus approximately 11 months in the combined SoC arms.
  • The company reports that all patients remaining in the 30 mg onvansertib plus FOLFIRI/bev arm have been on treatment for at least 21 months, with the longest duration over 29 months.

Concerns

  • Royalty revenues were $171 thousand for the quarter and $316 thousand for the nine months, so the company has no meaningful revenue base.
  • Cash, cash equivalents and short-term investments of approximately $33.8 million compare with net cash used in operating activities of approximately $33.9 million for the nine months, and the company guides to runway only to the end of Q3 2027.
  • Total stockholders' equity fell to $28,098 thousand from $45,388 thousand at December 31, 2025.
  • The filing does not state the funding requirement or source for the planned Phase 3 trial.
  • Only 6 patients remain on the FOLFIRI/bev regimen as of September 28, 2026, with 5 in the onvansertib arms and 1 on SoC, which limits the number of patients still on treatment in the Phase 2 trial.
  • The company has an interim Chief Medical Officer, appointed in October 2026.

What to watch

  • Timing and funding of the registrational Phase 3 trial in first-line RAS-mutated mCRC, with a potential start in Q1 2027 as stated by the company.
  • Updated Phase 2 PFS data as the 30 mg onvansertib plus FOLFIRI/bev arm matures, including whether the median PFS is reached.
  • Cash runway, which the company places at the end of Q3 2027, and any further financing.
  • Operating expense trend, following the year-to-date decrease in total operating expenses to $32,000 thousand.
  • Updated CMML data from the investigator-sponsored trial, scheduled for presentation at ASH on December 13, 2026.
  • Appointment of a permanent Chief Medical Officer, given that Dr. Alland is serving as interim.

Balance sheet and cash flow

  • Cash and cash equivalents were $12,060 thousand and short-term investments were $21,730 thousand as of September 30, 2026. The company describes the combined total as approximately $33.8 million in cash, cash equivalents and short-term investments.
  • Cash and cash equivalents at December 31, 2025 were $17,470 thousand and short-term investments were $40,834 thousand.
  • Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $33.9 million, an increase of $2.0 million from $31.9 million for the same period in 2025.
  • Total liabilities were $8,316 thousand as of September 30, 2026, compared with $16,496 thousand as of December 31, 2025. Accounts payable was $693 thousand, compared with $8,087 thousand at December 31, 2025.
  • Management believes current cash resources are sufficient to fund operations to the end of the third quarter of 2027, based on its current expectations and projections.

Analysis

Cardiff Oncology reported a third-quarter 2026 net loss of $(8,857) thousand, compared with $(11,258) thousand in the third quarter of 2025, and a nine-month net loss of $(30,434) thousand against $(38,635) thousand a year earlier. Net loss per share was $(0.12) for the quarter and $(0.43) for the nine months, against $(0.17) and $(0.58). All income statement figures are GAAP as printed in thousands. The company has no product revenue; royalty revenues were $171 thousand for the quarter and $316 thousand for the nine months, and the nine-month figure is below the prior-year $350 thousand.

The cost base fell substantially. Total operating expenses for the nine months were $32,000 thousand, a decrease of $9.5 million from $41,483 thousand. The company attributes the $12.5 million decline in R&D to completion of clinical trials, fewer patients on treatment in the Phase 2 mCRC trial, reduced preclinical activity and completion of CMC work for the planned Phase 3. SG&A moved the other way, rising $3.1 million to $14,291 thousand for the nine months, which the company says was driven by legal and professional fees tied to the NMS dispute and by employee severance. Interest income declined to $1,251 thousand for the nine months from $2,492 thousand, a figure that tracks the lower cash balance the filing reports.

The balance sheet is the main constraint in this release. Cash, cash equivalents and short-term investments were approximately $33.8 million at September 30, 2026. Net cash used in operating activities for the nine months was approximately $33.9 million, up $2.0 million from $31.9 million. Total assets fell to $36,414 thousand from $61,884 thousand at December 31, 2025, and stockholders' equity fell to $28,098 thousand from $45,388 thousand. The July 2026 registered direct offering raised net proceeds of approximately $9.1 million. Management states that current resources fund operations to the end of the third quarter of 2027.

The clinical narrative is the core of the update. The company reports that median PFS has not been reached in the 30 mg onvansertib plus FOLFIRI/bev arm, the proposed Phase 3 regimen, against approximately 11 months in the combined SoC arms. Only 6 patients remain on the FOLFIRI/bev regimen as of September 28, 2026, so these maturing data rest on a small number of patients still on treatment. The company says patients remaining in the 30 mg arm have been on treatment for at least 21 months. The filing does not give hazard ratios, confidence intervals or event counts, so the strength of the separation cannot be assessed from this release.

The company gives no quantitative guidance. It describes the Phase 3 trial as potentially starting in Q1 2027 and does not state the cost or financing plan for it. Against a cash position that the company places at the end of Q3 2027, the timing of any new financing is the central open question. Governance also changed in the quarter, with Dr. Leila Alland appointed interim Chief Medical Officer in October 2026.

On balance, the period shows lower spending and a narrower loss, alongside a shrinking cash base and no revenue of scale. The prior-period outlook was not provided, so no comparison against guidance is made.

Management, verbatim

We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms.

Mani Mohindru, PhD, President and Chief Executive Officer, Cardiff Oncology

There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.

Mani Mohindru, PhD, President and Chief Executive Officer, Cardiff Oncology

Not in the filing

stated, not guessed
  • No company guidance is provided in the filing for revenue, expenses, cash or timing beyond the Phase 3 start window of potentially Q1 2027 and the runway to the end of Q3 2027.
  • No prior-year percentage changes are printed for any line; yoy_change is therefore null where no dollar change is stated.
  • Prior-quarter (Q2 2026) figures are not printed in the filing, so qoq_change is null throughout.
  • The balance sheet compares September 30, 2026 with December 31, 2025, not with September 30, 2025, so prior_year is null for total assets and stockholders' equity.
  • Cash and cash equivalents and short-term investments are printed separately; the combined $33.8 million is the company's own figure.
  • Third-quarter operating cash flow and quarter-level cash flow statement data are not printed.
  • Segment or product-line revenue breakdown is not provided; royalty revenue is the only revenue line.
  • Phase 3 trial cost, funding source and enrollment size are not stated.
  • Median PFS figures are given without hazard ratios, confidence intervals, event counts or statistical tests.
  • No non-GAAP measures are presented in the filing.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CRDF earnings dates

When is Cardiff Oncology's next earnings date?
AlphAI has no date for CRDF yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.